Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: -- Be empowered with MS views and news. Opt-in with us:

~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Thursday, June 5, 2014

Biogen Idec Investigates Tysabri in Secondary-Progressive Multiple Sclerosis Patients

Biogen Idec is currently sponsoring a clinical trial evaluating its therapy Tysabri (natalizumab) in patients with secondary-progressive multiple sclerosis. Although relapse-remitting multiple sclerosis is more common and well-researched, the National Multiple Sclerosis Society estimates approximately half of relapse-remitting patients will transition to secondary-progressive within 19 years of diagnosis.
Biogen IdecThe Phase 3b clinical trial is a multicenter, international study known as “A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis,” or simply “ASCEND in SPMS.” It is a two-part study, with part one placebo-controlled and part two open-label.
The primary objective of the placebo-controlled study is to evaluate slowed disability progression in patients treated with natalizumab. Patients will be evaluated with the Expanded Disability Status Scale, Timed 25-Foot Walk, and/or 9-Hole Peg Test. Secondary objectives will focus on clinical outcomes such as brain volume using MRI scans.
During the open-label extension study, patients will be monitored for adverse and serious adverse effects to solidify the safety profile of natalizumab. Secondary measures will continue to evaluate disability progression.
An estimated 856 patients are participating in the trial, and natalizumab will be administered once a month intravenously. Patients will receive treatment for a total of 96 weeks, and the study duration is 108 weeks. The trial is predicted to end in December 2014.

To comment - click the comment link shown below
Share our Articles with others
MS Views and News / Stu's Views & MS News 
provides education, information and resources 
for those affected by Multiple Sclerosis

To Keep CURRENT  and up to date with MS News and Information
Sign-up at: 


JOIN our Facebook Page:


Thank you   

Stu's Views & MS News, is a publication of: 

No comments: